Related references
Note: Only part of the references are listed.Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
Masaomi Iyo et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2021)
Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia
Alejandra Caqueo-Urizar et al.
HEALTHCARE (2021)
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
Masaomi Iyo et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Prevalence of suicide attempts in individuals with schizophrenia: a meta-analysis of observational studies
Li Lu et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2020)
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
George A. Keepers et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis
Robin Michael Van Eck et al.
SCHIZOPHRENIA BULLETIN (2018)
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
Donald C. Goff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis
Carsten Hjorthoj et al.
LANCET PSYCHIATRY (2017)
Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
Christoph U. Correll et al.
CNS SPECTRUMS (2016)
Impact of Cognitive and Social Cognitive Impairment on Functional Outcomes in Patients With Schizophrenia
Michael F. Green
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Global economic burden of schizophrenia: a systematic review
Huey Yi Chong et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2016)
An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review
Jason C. Simeone et al.
BMC PSYCHIATRY (2015)
Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies
A. Loebel et al.
EUROPEAN PSYCHIATRY (2015)
Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study
Stephen M. Stahl et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
Henry A. Nasrallah et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
Erika Jaaskelainen et al.
SCHIZOPHRENIA BULLETIN (2013)
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
Antony Loebel et al.
SCHIZOPHRENIA RESEARCH (2013)
Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
Antony Loebel et al.
SCHIZOPHRENIA RESEARCH (2013)
Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
Herbert Y. Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
Kelly Posner et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
Tadashi Ishibashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up
P Milev et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Share Paper
